Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004

Keizo Yamaguchi, Yoshikazu Ishii, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Akira Suwabe, Kumiko Yamahata, Mitsuo Kaku, Keiji Kanemitsu, Hiroshi Yoshida, Kyouko Nishiyama, Masami Murakami, Ayako Takahashi, Kouichi Itoh, Tomoko Oohara, Fumio Nomura, Masaharu Watanabe, Harushige KannoMasanori Aihara, Shigefumi Maesaki, Giichi Hashikita, Kazunori Miyake, Toyoko Oguri, Jun Okada, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Masahiko Okada, Sugako Kobayashi, Toshinobu Horii, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Toshiaki Komori, Satoshi Ichiyama, Shigetaka Maeda, Kiyoharu Yamanaka, Yoko Murata, Masaru Komatsu, Shohiro Kinoshita, Tomohiko Taminato, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuchika Kusano, Euchiro Mihara, Masayuki Kambe, Hideyuki Itaha, Junko Ono, Hisae Yoshimura, Yoichi Hirakata, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC 90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-β-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC 90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 μg/ml→1 μg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.

Original languageEnglish
Pages (from-to)655-689
Number of pages35
JournalJapanese Journal of Antibiotics
Volume58
Issue number6
Publication statusPublished - Dec 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Yamaguchi, K., Ishii, Y., Iwata, M., Watanabe, N., Uehara, N., Yasujima, M., Kasai, T., Suwabe, A., Yamahata, K., Kaku, M., Kanemitsu, K., Yoshida, H., Nishiyama, K., Murakami, M., Takahashi, A., Itoh, K., Oohara, T., Nomura, F., Watanabe, M., ... Hiramatsu, K. (2005). Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Japanese Journal of Antibiotics, 58(6), 655-689.